A total of 401 patients participated in the 12-week, double-blind, placebo-controlled study, designed to assess the efficacy of duloxetine 60mg once daily on the reduction of pain severity in patients with chronic low back pain.
In the study, duloxetine-treated patients experienced a greater improvement on BPI average pain scale, compared to placebo, in chronic low back pain (p<0.005).
Adults (N=401) with non-neuropathic chronic low back pain and pain intensity of 4 on the 11-point BPI average pain scale, were treated with either duloxetine 60mg once daily (N=198) or placebo (N=203) for 12 weeks in this randomized, double-blind trial. The primary measure was BPI average pain.
Cymbalta is approved to treat major depressive disorder and generalized anxiety disorder, and to manage diabetic peripheral neuropathic pain and fibromyalgia.